LUND, SWEDEN--(Marketwire - April 22, 2010) -
Laquinimod - Teva extends its marketing and distribution rights for laquinimod
TASQ - preparations for Phase III trials under way
ANYARA - exploratory combination data presented
57-57 - exploratory clinical trial in progress
ISI - project proceeding according to plan
RhuDex™ - preclinical studies in progress
Net sales of SEK 2.8 M (2.2)
Operating loss of SEK 51.0 M (loss: 63.7)
Loss after tax of SEK 53.5 M (loss: 62.2)
Loss per share for the period amounted to SEK 0.83 (loss: 1.21)
After the end of the period a directed share issue raised approximately SEK 149 M for the company
For further information, please contact: Tomas Leanderson President and CEO Tel: +46 (0)46-19 20 95 Göran Forsberg VP Investor Relations & Business Development Tel: +46 (0)46-19 11 54 Hans Kolam CFO Tel: +46 (0)46-19 20 44 Active Biotech AB (Corp. Reg. No. 556223-9227) Box 724, SE-220 07 Lund Tel: +46 (0)46-19 20 00 Fax: +46 (0)46-19 11 00
This report is also available at www.activebiotech.com
[HUG#1406538]
Active Biotech Interim report January-March 2010: http://hugin.info/1002/R/1406538/359991.pdf
